Exagen Inc. reaffirmed earnings guidance for the full year ended December 31, 2023. For the year, the company expected total revenue of at least $50 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 USD | +0.71% | +1.81% | -29.15% |
04-26 | Exagen Inc. Announces Changes in Board of Directors | CI |
03-18 | Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.15% | 24.47M | |
+18.92% | 84.31B | |
-29.48% | 69.9B | |
+9.65% | 29.06B | |
+1.75% | 17.01B | |
-9.30% | 17.38B | |
+0.20% | 15.35B | |
+5.25% | 12.91B | |
+68.96% | 12.47B | |
-1.90% | 11.9B |
- Stock Market
- Equities
- XGN Stock
- News Exagen Inc.
- Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023